Pembrolizumab (MK-3475) in MM Patients With Residual Disease

NCT02636010 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Pembrolizumab

Sponsor

PETHEMA Foundation

Collaborators

[object Object]
[object Object]